Pharmaceutical / Drug Definition :
Inhibits conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; inactivates bradykinin and prostaglandins. Also increases plasma renin and potassium levels and reduces aldosterone levels, resulting in systemic vasodilation.
Enalaprilat (Enalaprilat Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Enalaprilat (Enalaprilat Suppliers)
- Processors Enalaprilat
- Repackers Enalaprilat
- Relabelers Enalaprilat
- Exporters Enalaprilat
- Importers Enalaprilat
For more information about Enalaprilat, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.